RT Journal Article
SR Electronic
T1 Implications of the Hippo Pathway Dysregulation in Uterine Leiomyosarcoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3331
OP 3336
DO 10.21873/anticanres.17152
VO 44
IS 8
A1 KYRIAZOGLOU, ANASTASIOS
A1 PAPACHRISTOU, DIONYSIOS J.
A1 MOUTAFI, MYRTO
A1 PAPAKOSTA, ALEXANDRA
A1 PAPATHEODORIDI, ALKISTIS
A1 KAPARELOU, MARIA
A1 KORAKITI, ANNA MARIA
A1 LIONTOS, MICHALIS
A1 DIMOPOULOS, MELETIOS ATHANASIOS
A1 ZAGOURI, FLORA
YR 2024
UL http://ar.iiarjournals.org/content/44/8/3331.abstract
AB Background/Aim: Uterine leiomyosarcomas (uLMS) are the most common mesenchymal tumors of the female genital tract. uLMS genetics encompass complex karyotypes with no specific molecular alterations. The Hippo pathway has been implicated in the pathogenesis of epithelioid hemangio-endotheliomas and endometrial sarcomas. Hippo pathway effectors are YAP1 and TAZ co-transcriptional factors. Patients and Methods: We studied Hippo pathway in a series of 32 uLMS patients and its association with clinicopathological parameters. Materials and Methods: Immunohistochemical analysis of YAP1 and TAZ proteins accompanied with fluorescent in situ hybridization study of YAP1 gene was performed in patient samples. Age, sex, tumor size, stage at the time of diagnosis and treatment have been analyzed. Overall survival (OS) was calculated from the time of diagnosis until death, loss of follow up or data cut-off. Results: Hippo signaling was found to be dysregulated in 20 (62.5%) patients with uLMS. Regarding OS we detected a trend of Hippo deregulation, designating it as a positive prognostic factor. Conclusion: The Hippo pathway is implicated in uLMS oncogenesis, since nuclear expression of YAP1 was detected in 17 (53.1%) of the 32 patients with immunohistochemistry and YAP1 amplification was found in 8 (25%) patients.